Mason L, Edwards J, Moore R A, McQuay H J
Pain Research Unit, Churchill Hospital, Old Road, Headington, Oxford, UK, OX3 7LJ.
Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD004308. doi: 10.1002/14651858.CD004308.pub2.
Indometacin is a non-steroidal anti-inflammatory drug (NSAID) used most commonly for the treatment of inflammation and pain resulting from rheumatic disease (arthritis), and less commonly in postoperative pain management. When taken for chronic pain conditions, indometacin has been associated with a high incidence of adverse events. The benefits and harms of orally-administered indometacin for postoperative pain are not clear.
To determine the efficacy of a single dose of oral indometacin compared with placebo in treating acute postoperative pain in adults, and to analyse information relating to adverse events.
We searched the Cochrane Central Register of Controlled Trials in The Cochrane Library (Issue 3, 2004), MEDLINE, EMBASE and the Oxford Pain Relief Database for relevant studies. Additional studies were sought from the reference lists of retrieved reports.
Studies were included in the review if they were randomised, double blind, placebo-controlled clinical trials using a single oral dose of indometacin in adults with acute postoperative pain.
Trials were assessed independently by two authors. Pain relief or pain intensity data were extracted and converted into dichotomous information to give the number of patients with at least 50% pain relief over four to six hours. The relative benefit for at least 50% pain relief was calculated.
One trial of 59 women with post-episiotomy pain met the inclusion criteria. The dose of indometacin assessed against placebo was 50 mg, and the results concluded that indometacin was not significantly better than placebo for relieving postoperative pain at four to six hours. There was insufficient information to conduct further efficacy analyses or assess adverse events.
REVIEWERS' CONCLUSIONS: Conclusions about the clinical efficacy of indometacin for postoperative cannot be made until more trials are conducted for a variety of surgical procedures, and different doses of indometacin are assessed.
吲哚美辛是一种非甾体抗炎药(NSAID),最常用于治疗风湿性疾病(关节炎)引起的炎症和疼痛,较少用于术后疼痛管理。用于慢性疼痛状况时,吲哚美辛与不良事件的高发生率相关。口服吲哚美辛用于术后疼痛的利弊尚不清楚。
确定单剂量口服吲哚美辛与安慰剂相比治疗成人急性术后疼痛的疗效,并分析与不良事件相关的信息。
我们检索了《 Cochr ane图书馆》(2004年第3期)中的 Cochr ane对照试验中央登记册、MEDLINE、EMBASE和牛津疼痛缓解数据库以查找相关研究。还从检索报告的参考文献列表中寻找其他研究。
如果研究是随机、双盲、安慰剂对照的临床试验,且在患有急性术后疼痛的成人中使用单剂量口服吲哚美辛,则纳入本综述。
由两位作者独立评估试验。提取疼痛缓解或疼痛强度数据并转换为二分信息,以得出在四至六小时内疼痛缓解至少50%的患者人数。计算至少50%疼痛缓解的相对益处。
一项针对59名会阴切开术后疼痛女性的试验符合纳入标准。与安慰剂对照评估的吲哚美辛剂量为50毫克,结果得出吲哚美辛在四至六小时缓解术后疼痛方面并不显著优于安慰剂。没有足够的信息进行进一步的疗效分析或评估不良事件。
在针对各种手术程序进行更多试验并评估不同剂量的吲哚美辛之前,无法得出关于吲哚美辛对术后临床疗效的结论。